{
  "General": [
    "Cancer Type",
    "Generic name",
    "Brand name",
    "Company EU",
    "Company US",
    "Company China",
    "Sponsors",
    "Preclinical or Clinical stage",
    "Clinical Trial Phase",
    "Immune Checkpoint Inhibitor (ICI) Naive",
    "Immune Checkpoint Inhibitor (ICI) failed",
    "Biosimilar",
    "Line of Treatment",
    "NCT Number",
    "Mechanism of action",
    "Target Protein",
    "Development status",
    "Type of therapy",
    "Trial name",
    "Type of dosing",
    "Number of doses per year",
    "Primary endpoint",
    "Secondary endpoint",
    "Median Age",
    "Biomarker Inclusion",
    "Biomarkers Inclusion Criteria",
    "Biomarkers Exclusion Criteria",
    "Major country where clinical trial is conducted",
    "Study start date",
    "Study completion date",
    "First results",
    "EU filing date",
    "EU approval date",
    "Months needed to gain EU approval",
    "US filing date",
    "US approval date",
    "Months needed to gain US approval",
    "China filing date",
    "China approval date",
    "Months needed to gain China approval"
  ],
  "Efficacy": [
    "Objective response rate (ORR)",
    "Complete Response (CR)",
    "Pathological Complete Response (pCR)",
    "Complete Metabolic Response (CMR)",
    "Disease Control Rate or DCR",
    "Clinical Benefit Rate (CBR)",
    "Duration of Response (DOR) rate",
    "Progression free survival (PFS) rate at 6 months",
    "Progression free survival (PFS) rate at 12 months",
    "Progression free survival (PFS) rate at 18 months",
    "Progression free survival (PFS) rate at 24 months",
    "Progression free survival (PFS) rate at 48 months",
    "Overall survival (OS) rate at 6 months",
    "Overall survival (OS) rate at 12 months",
    "Overall survival (OS) rate at 18 months",
    "Overall survival (OS) rate at 24 months",
    "Overall survival (OS) rate at 48 months",
    "Number of patients",
    "Progression free survival (PFS)",
    "Length of measuring PFS",
    "p-value of PFS",
    "Hazard ratio (HR) PFS",
    "Overall survival (OS)",
    "Length of measuring OS",
    "p-value of OS",
    "Hazard ratio (HR) OS",
    "Event-Free Survival (EFS)",
    "p-value of EFS",
    "Hazard ratio (HR) EFS",
    "Recurrence-Free Survival (RFS)",
    "p-value of RFS",
    "Length of measuring RFS",
    "Hazard ratio (HR) RFS",
    "Metastasis-Free Survival (MFS)",
    "Length of measuring MFS",
    "Hazard ratio (HR) MFS",
    "Time to response (TTR)",
    "Time to Progression (TTP)",
    "Time to Next Treatment (TTNT)",
    "Time to Treatment Failure (TTF)",
    "Median Duration of response or DOR"
  ],
  "Safety": [
    "Rate of Treatment-emergent adverse events (TEAE) led to treatment discontinuation",
    "Rate of adverse events (AEs) leading to discontinuation",
    "Rate of Treatment-emergent adverse events (TEAE) led to death",
    "Rate of AEs leading to death",
    "Adverse events (AE)",
    "Treatment emergent adverse events (TEAE)",
    "Treatment-related adverse events (TRAE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3 higher adverse events (AE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3 higher treatment emergent adverse events (TEAE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3 higher treatment-related adverse events (TRAE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3 higher treatment-emergent adverse events (TEAE)",
    "Immune related adverse events (irAEs)",
    "Serious Adverse Events (SAE)",
    "Serious treatment emergent adverse events (TEAE)",
    "Serious treatment related adverse events (TRAE)",
    "Cytokine Release Syndrome or CRS",
    "Thrombocytopenia",
    "Neutropenia",
    "Leukopenia",
    "Nausea",
    "Anemia",
    "White blood cell (WBC) decreased",
    "Grade ≥3 or Gr 3 or Gr 3-5 or Grade 3+ or Grade 3-5 or Grade 3-4 or Grade 3 higher Cytokine Release Syndrome or CRS",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 or Grade 3 higher Thrombocytopenia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 or Grade 3 higher Neutropenia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 or Grade 3 higher Leukopenia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 or Grade 3 higher Nausea",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 or Grade 3 higher Anemia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3 higher White blood cell (WBC) decreased"
  ]
} 